Literature DB >> 15141340

Successful treatment of Wernicke encephalopathy in terminally ill cancer patients: report of 3 cases and review of the literature.

Hideki Onishi1, Chiaki Kawanishi, Masanari Onose, Tomoki Yamada, Hideyuki Saito, Akira Yoshida, Kazumasa Noda.   

Abstract

Although Wernicke encephalopathy has been reported in the oncological literature, only one terminally ill cancer patient with Wernicke encephalopathy has been reported. Wernicke encephalopathy, a potentially reversible condition, may be unrecognized in terminally ill cancer patients. In this communication, we report three terminally ill cancer patients who developed Wernicke encephalopathy. Early recognition and subsequent treatment resulted in successful palliation of delirium. Two of the three patients did not show the classical triad of Wernicke encephalopathy. Common clinical symptoms were delirium and poor nutritional status. Intravenous thiamine administration dramatically improved the symptoms of delirium in all three patients. In terminally ill cancer patients, clinicians must remain aware of the possibility of Wernicke encephalopathy when patients with a poor nutritional status present with unexplained delirium. Early intervention may correct the symptoms and prevent irreversible brain damage and the quality of life for the patient may improve.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15141340     DOI: 10.1007/s00520-004-0637-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  23 in total

1.  Severe acute metabolic acidosis and Wernicke's encephalopathy following chemotherapy with 5-fluorouracil and cisplatin: case report and review of the literature.

Authors:  K Kondo; M Fujiwara; M Murase; Y Kodera; S Akiyama; K Ito; H Takagi
Journal:  Jpn J Clin Oncol       Date:  1996-08       Impact factor: 3.019

Review 2.  Wernicke-Korsakoff syndrome.

Authors:  C Zubaran; J G Fernandes; R Rodnight
Journal:  Postgrad Med J       Date:  1997-01       Impact factor: 2.401

3.  A symptom rating scale for delirium.

Authors:  P T Trzepacz; R W Baker; J Greenhouse
Journal:  Psychiatry Res       Date:  1988-01       Impact factor: 3.222

4.  A retrospective study of the psychiatric management and outcome of delirium in the cancer patient.

Authors:  S M Olofsson; M A Weitzner; A D Valentine; W F Baile; C A Meyers
Journal:  Support Care Cancer       Date:  1996-09       Impact factor: 3.603

Review 5.  Clinical chemistry of thiamin.

Authors:  R E Davis; G C Icke
Journal:  Adv Clin Chem       Date:  1983       Impact factor: 5.394

6.  Wernicke's encephalopathy in a non-alcoholic man: case report and brief review.

Authors:  A Munir; S A Hussain; D Sondhi; J Ameh; F Rosner
Journal:  Mt Sinai J Med       Date:  2001-05

7.  Wernicke encephalopathy in nonalcoholic patients.

Authors:  Paul R Ogershok; Aamer Rahman; Scott Nestor; James Brick
Journal:  Am J Med Sci       Date:  2002-02       Impact factor: 2.378

8.  Psychiatric morbidity in terminally ill cancer patients. A prospective study.

Authors:  H Minagawa; Y Uchitomi; S Yamawaki; K Ishitani
Journal:  Cancer       Date:  1996-09-01       Impact factor: 6.860

9.  Delirium in terminally ill cancer patients.

Authors:  M J Massie; J Holland; E Glass
Journal:  Am J Psychiatry       Date:  1983-08       Impact factor: 18.112

10.  Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy.

Authors:  C G Harper; M Giles; R Finlay-Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-04       Impact factor: 10.154

View more
  11 in total

1.  Risk of thiamine deficiency and Wernicke's encephalopathy after gastrointestinal surgery for cancer.

Authors:  Angelo Restivo; Mauro Giovanni Carta; Anna Maria Giulia Farci; Laura Saiu; Gian Luigi Gessa; Roberta Agabio
Journal:  Support Care Cancer       Date:  2015-05-02       Impact factor: 3.603

Review 2.  Palliative treatment of thiamine-related encephalopathy (Wernicke's encephalopathy) in cancer: A case series and review of the literature.

Authors:  Elie Isenberg-Grzeda; Alan John Hsu; Vaios Hatzoglou; Christian Nelso; William Breitbart
Journal:  Palliat Support Care       Date:  2014-10-23

3.  Wernicke's encephalopathy in advanced gastric cancer.

Authors:  Eun Suk Jung; Obin Kwon; Soo Hyun Lee; Ki Byung Lee; Joo Hoon Kim; Sang Hyun Yoon; Gun Min Kim; Hei-Cheul Jeung; Sun Young Rha
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

4.  Wernicke's encephalopathy in a patient with unresectable gastric carcinoma and literature review.

Authors:  Sema Yilmaz Rakici; Sema Dogan Erdemli; Zihni Acar Yazici; Ercument Cengiz; Ozlem Gunay Acar; Gulnihal Tufan
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 5.  Delirium in patients with cancer: assessment, impact, mechanisms and management.

Authors:  Peter G Lawlor; Shirley H Bush
Journal:  Nat Rev Clin Oncol       Date:  2014-09-02       Impact factor: 66.675

Review 6.  Wernicke's encephalopathy: expanding the diagnostic toolbox.

Authors:  Mary E Lough
Journal:  Neuropsychol Rev       Date:  2012-05-11       Impact factor: 7.444

7.  Oncologic emergency in patients with skeletal metastasis of unknown primary.

Authors:  Tomoaki Torigoe; Jungo Imanishi; Yasuo Yazawa; Tadaaki Koyama; Yuho Kadono; Hiromi Oda; Kazuo Saita
Journal:  Acute Med Surg       Date:  2021-02-04

8.  Association between malignancy and non-alcoholic Wernicke's encephalopathy: a case report and literature review.

Authors:  Evan Y Choi; William A Gomes; Missak Haigentz; Jerome J Graber
Journal:  Neurooncol Pract       Date:  2015-09-22

Review 9.  Susceptibility of the cerebellum to thiamine deficiency.

Authors:  Patrick J Mulholland
Journal:  Cerebellum       Date:  2006       Impact factor: 3.648

10.  Subclinical thiamine deficiency identified by pretreatment evaluation in an esophageal cancer patient.

Authors:  Akira Yoshioka; Izumi Sato; Hideki Onishi; Mayumi Ishida
Journal:  Eur J Clin Nutr       Date:  2020-09-07       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.